Q-omics provides the consensus-scored FGF7 profile across patient tissues and cancer cell-line models. FGF7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FGF7 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, FGF7 RNA expression shows 21,722 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KIRC, and LSCC as cancer lineages where FGF7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FGF7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FGF7 survival associations across molecular data types. FGF7 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FGF7 RNA expression–survival associations across cancer types. High FGF7 expression shows unfavorable associations in KIRP and BLCA, but favorable associations in SKCM, LUAD, UCS and SARC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FGF7 RNA expression.
This table summarizes FGF7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FGF7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FGF7 shows lower tumor expression in KIRC, THCA, KIRP, UCEC, LUSC and LUAD. The KIRC box plot shows higher FGF7 RNA expression in normal versus tumor tissue (log2 FC = −1.637, t-test p < 0.001).
This table shows molecular features associated with FGF7 in patient tissues and cancer cell lines. In patient samples, FGF7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FGF7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
